Skip header and navigation

56 records – page 1 of 6.

Document Type
Evidence Search Report
Review Code
LAB041402-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB041402-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 14; Document no.: LAB041402-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 42 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041402 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
The majority of patients (>50%) appear to seroconvert between 8-14 days following the onset of symptoms.
Nearly all patients (>80%) seroconvert >15 days following the onset of symptoms.
The IgM response is detected earlier (median 12 days) than the IgG response (median 14 days).
Seroconversion appears to follow clinical recovery in most cases.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Vanstone, J; Reeder, B; Duncan, V. At what time in the disease timeline of COVID-19 do antibodies develop? 2020 Apr 15; Document no.: LAB041402 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 4 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Table
Review Code
EPM052101 RR Table
Question Submitted
May 21, 2020
Date Completed
May 25, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Document Type
Table
Review Code
EPM052101 RR Table
Question Submitted
May 21, 2020
Date Completed
May 25, 2020
Status
3. Completed
Research Team
Epidemiology & Modelling
Category
Clinical Presentation
Epidemiology
Subject
Mortality
Hospitalization
Priority Level
Level 2 completed within 8 hours
Cite As
Williams-Roberts, H; Basran, J; Dalidowicz, M; Mueller, M. What are the fatality rates associated with COVID-19 for ICU, hospitalized, and patients discharged from ICU to general wards? 2020 May 25; Document no.: EPM052101 RR Table. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. (CEST table)
Related Documents
Documents

EPM052101 RR Table

Download File
Less detail
Document Type
Evidence Search Report
Review Code
LAB041501-01 ESR
Question Submitted
April 15, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB041501-01 ESR
Question Submitted
April 15, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 15; Document no.: LAB041501-01 ESR In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 22 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041501 RR
Question Submitted
April 15, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041501 RR
Question Submitted
April 15, 2020
Date Completed
April 17, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Seroconversion occurs in majority of COVID-19 patients from the second week following symptomonseton.
Between 7.8 -43.6% of suspect cases and 4.7% of asymptomatic individuals with negative nucleic acid test (rt-PCR) test positive for antibodies against SARS-CoV-2.
An increase in antibody titrescorrelates with a neutralizing antibody response and positive recovery of COVID-19 patients with mild to moderate symptoms.
Although higher antibody titreand more robust antibody response are observed in severe and critically ill patients, those antibodies may not effectively clear virus and higher antibody levels may be associated with a worse clinical progress.
Category
Clinical Presentation
Subject
Antibodies
Natural History
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the clinical course of disease? 2020 Apr 17; Document no.: LAB041501 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 5 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB041401-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB041401-01 ESR
Question Submitted
April 14, 2020
Date Completed
April 14, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Antibodies
Serology
Priority Level
Level 2 completed within 8 hours
Cite As
Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 14; Document no.: LAB041401-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 20 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB041401 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB041401 RR
Question Submitted
April 14, 2020
Date Completed
April 15, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Moderate to strong grade evidence show the overall sensitivityrangeof IgM, IgG, and combined IgM/IgG are 48.1% to 94.1%, 64.7% to 100%, 83% to 100%, respectively.
IgM/IgG combined assay, with the posterior probability of 99.15%, has greater accuracyand sensitivity than a single IgM or IgG test.
The sensitivity of antibody tests is extremely low (~ 11.1%) in the first week following the onsetof symptoms but increasesrapidlyduring the second week.
IgG and IgM titers in patients with severe disease arehigher than those in the non-severe patients.
Antibody testsmay detect the presence of COVID-19 in asymptomatic individuals with negative rt-PCRresults.
Category
Clinical Presentation
Subject
Testing
Serology
Antibodies
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Howell-Spooner, B. How well does the presence and level of antibodies predict the presence or absence of the disease? 2020 Apr 15; Document no.: LAB041401 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 9 p. (CEST rapid review report)
Similar Reviews
PH042401 RR
EPM051201 RR
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Evidence Search Report
Review Code
LAB040803-01 ESR
Question Submitted
April 8, 2020
Date Completed
April 8, 2020
Status
3. Completed
Research Team
Laboratory
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Duncan, V. Is the IgM or IgG immune response protective? 2020 Apr 8; Document no.: LAB040803-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 13 p. (CEST evidence search report)
Related Documents
Documents
Less detail
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Document Type
Rapid Review
Review Code
LAB040803 RR
Question Submitted
April 8, 2020
Date Completed
April 11, 2020
Status
3. Completed
Research Team
Laboratory
Key Findings
Low grade evidence shows IgG and IgM antibody response correlates with neutralizingantibody titerand viral clearance, which is suggestive of protective humoral immunity inCOVID-19 patients with mild to moderate symptoms.
There is no available evidence with which to estimate the durability of this protective response. However, if the immune response to SARS-CoV-2 resembles that toward SARS-CoV, this protective humoral immunity may persist for several years.
Higher IgG antibody titersand a robustresponse were noted in severe to criticallyill patients and were associated with lower viral clearance and a worse clinical prognosis.
Low grade evidence suggests that convalescent plasma treatment may improve the clinical status of critically ill COVID-19 patients(one case series with only five patients enrolled).
Category
Clinical Presentation
Subject
Testing
Serology
Immunity
Natural History
Population
All
Priority Level
Level 2 completed within 8 hours
Cite As
Wang, H; Reeder, B; Duncan, V; Is the IgM or IgG immune response protective? 2020 Apr 11; Document no.: LAB040803 RR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 6 p. (CEST rapid review report)
Related Documents
Documents
Less detail
Document Type
Evidence Search Report
Review Code
INF092801-01 ESR
Question Submitted
September 28, 2020
Date Completed
September 30, 2020
Status
3. Completed
Research Team
Infectious Disease
Document Type
Evidence Search Report
Review Code
INF092801-01 ESR
Question Submitted
September 28, 2020
Date Completed
September 30, 2020
Status
3. Completed
Research Team
Infectious Disease
Category
Clinical Presentation
Subject
Mortality
Risk
Surgical Procedures
Population
All adults
Clinical Setting
Medicine Unit
Priority Level
Level 3 Two weeks (14 days)
Cite As
Howell-Spooner, B; Dalidowicz, M. Is there increased morbidity or mortality peri-operatively for symptomatic, asymptomatic, post-COVID patients? 2020 Sep 30; Document no.: INF092801-01 ESR. In: COVID-19 Rapid Evidence Reviews [Internet]. SK: SK COVID Evidence Support Team, c2020. 41 p. (CEST evidence search report)
Related Documents
Documents
Less detail

56 records – page 1 of 6.